The US Food and Drug Administration (FDA) has accepted a pre-market tobacco product application from TJP Labs for its L!X nicotine pouch product for review.
TJP Labs has created the L!X nicotine pouch for adult users (21 years and older) who are unable or unwilling to quit using nicotine products, particularly those who wish to transition to non-combustible oral products, according to a statement by TJP Labs CEO David Richmond-Peck.
He said, "The acceptance of our application by the FDA shows our team's dedication to providing alternative products for adult users that may reduce harm associated with traditional combustible tobacco products. Our factory's Canadian Health Department drug establishment license (DEL), natural health product site license, ISO 9001:2015, HACCP, and cGMP certifications demonstrate TJP Labs' strict quality standards and will further enhance our ability to serve the high-volume international market.
TJP Labs is a top-tier full-service contract manufacturer for next-generation products, specializing in oral nicotine pouches, caffeine, and other health supplements delivery solutions. The company is headquartered in Pickering, Ontario, Canada.
The L!X nicotine pouches are sold by L!X Innovations, a subsidiary of TJP Lab.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
